15 August 2018
Visiongain’s new report Pharma Clinical Trial Services Market Report : Early Phase Services, Late Phase Services, Other Services, Pharma, Biotech, Other End-Users, Cancer, Cardiovascular Diseases, CNS, Infectious Diseases, Metabolic Diseases, Other Diseases indicates that the pharma clinical trial sales market will see $61.92bn in spending in 2021.
The pharma clinical trial services market is expected to grow at a CAGR of 9.5% in the first half of the forecast period. The market is expected to grow at a CAGR of 9.8% from 2016-2027. The pharma clinical trial services market is estimated at $39.56bn in 2016 dominated by the late-phase services, which held 56% of share.
The lead analyst of the report said: “The pharma clinical trial services market is driven by several factors, which include the rise in research and development activities by biopharmaceutical organizations, increasing importance of contract research organizations in the emerging markets, and growth in biopharmaceutical research and development expenditures.
However, challenges such as patient recruitment and retention as well as regulatory challenges are some of the factors hampering the growth of this market.”
The 188-page report contains 145 charts that add visual analysis in order to explain the developing trends within the pharma clinical trial services market.
Visiongain provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the leading segments by type of services (early phase, late phase and other services), end-users (pharma, biotech companies and other end-users) and therapeutic area (Cancer, Cardiovascular, CNS, Infectious Diseases, Metabolic Diseases and other Diseases).
The 188-page report offers market forecasts for the US, Rest of North America, Germany, UK, France, Italy, Spain, Russia, Central and Eastern Europe, Rest of Europe, China, Japan, India, South Korea, Rest of APAC, Latin America, Brazil, Middle East and Africa.
Moreover, our work discusses the leading companies in the pharma clinical trial services market.
The report Pharma Clinical Trial Services Market and Industry Forecast 2017-2027: Early Phase Services, Late Phase Services, Other Services, Pharma, Biotech, Other End-Users, Cancer, Cardiovascular Diseases, CNS, Infectious Diseases, Metabolic Diseases, Other Diseases report will be of value to anyone who wants to better understand the pharma clinical trial services market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the pharma clinical trial services market.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.
Visiongain publishes reports produced by its analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.
25 November 2020
Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth
24 November 2020
Increasing prevalence of cardiovascular diseases is increasing demand of biological imaging reagents for the diagnosis and treatment of cardiovascular diseases due to this reason increasing prevalence of cardiovascular diseases is acting as a driver for biological imaging reagent market.
13 November 2020
Hypertensive is the most common disease around the world. However, number of people suffering from hypertensive has increased very significantly from last few years. Hypertensive can occur due to consumption of tobacco, too much salt (sodium) and little potassium in your diet, alcohol and to people being overweight or obese.